Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DI17KH
|
|||
| Drug Name |
TAS-1440
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60; ICD-9: 205] | Phase 1 | [1] | |
| Company |
Taiho Oncology; Astex Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Lysine-specific histone demethylase 1 (LSD) | Target Info | Inhibitor | [2] |
| Pathway Interaction Database | Notch signaling pathway | |||
| Coregulation of Androgen receptor activity | ||||
| Notch-mediated HES/HEY network | ||||
| Reactome | HDACs deacetylate histones | |||
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | ||||
| Factors involved in megakaryocyte development and platelet production | ||||
| WikiPathways | Factors involved in megakaryocyte development and platelet production | |||
| Androgen receptor signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04282668) A Study of TAS1440 With ATRA in Subjects With r/r AML. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Astex Pharmaceuticals. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.